Greg Divis, Avadel Pharmaceuticals CEO
October 17, 2024 11:26 AM EDTUpdated 12:01 PM
Pharma
FDA+

FDA ex­pands la­bel for Avadel's nar­colep­sy drug in­to chil­dren

Katherine Lewin

News Reporter

Avadel Phar­ma­ceu­ti­cals said its once-night­ly nar­colep­sy drug Lum­ryz can now be used to treat chil­dren old­er than 7 years of age.

The Thurs­day

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times